10-K/A: Akoya Biosciences Files Amendment No. 1 to Form 10-K, Providing Part III Information

Akoya Biosciences files an amendment to its 2024 Annual Report on Form 10-K to include information required by Part III, covering directors, executive officers, compensation, and corporate governance.

Summary

• Akoya Biosciences filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment provides information required by Part III of Form 10-K, which was previously omitted from the original filing.
• The information includes details about directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and principal accounting fees and services.
• The amendment also includes new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
• The original Form 10-K was filed with the SEC on March 17, 2025.
• The aggregate market value of common stock held by non-affiliates on June 30, 2024, was $61.7 million.
• As of April 14, 2025, there were 49,875,399 common shares outstanding.

Sentiment

Score: 7

Explanation: The document is primarily factual and descriptive, with a neutral tone. The announcement of the merger with Quanterix is a significant event that could be viewed positively by investors.

Positives

• The company has strong corporate governance practices with four standing committees.
• The board of directors is composed of experienced individuals with diverse backgrounds.
• The company has established a Scientific Advisory Board to provide strategic guidance.
• The company offers competitive compensation and benefits packages to its executives.
• The company maintains a 401(k) plan for its employees.
• The audit committee pre-approves all audit and non-audit services provided by the independent registered public accounting firm.

Negatives

• The aggregate market value of common stock held by non-affiliates on June 30, 2024, was relatively low at $61.7 million.
• One late Form 4 report was filed for each of Brian McKelligon, Johnny Ek, Jennifer Kamocsay, Frederic Pla, and Niroshan Ramachandran on March 1, 2024, which reported one late transaction each.

Risks

• The company's future performance is subject to various risks and uncertainties.
• The company's success depends on its ability to innovate and develop new products and technologies.
• The company faces competition from other companies in the life sciences industry.
• The company's financial results may be affected by changes in economic conditions.
• The company is subject to legal and regulatory risks.

Future Outlook

The company is set to merge with Quanterix Corporation, subject to the terms and conditions of the Merger Agreement.

Industry Context

Akoya Biosciences operates in the life sciences industry, specifically focusing on spatial biology solutions. The company's merger with Quanterix reflects a trend of consolidation in the diagnostics and life sciences tools market, as companies seek to expand their product offerings and market reach.

Comparison to Industry Standards

• Executive compensation appears to be in line with industry standards for companies of similar size and stage.
• Director compensation is also consistent with market practices.
• The company's corporate governance practices are generally aligned with best practices for publicly traded companies.

Related Party Transactions

• The company purchases reagent kits from Argonaut Manufacturing Services, a portfolio company of Telegraph Hill Partners, incurring costs of goods sold of approximately $3.5 million in 2024.
• Some directors are affiliated with entities that beneficially own or owned 5% or more of the company's common stock.

Stakeholder Impact

• Shareholders: The merger with Quanterix could result in a change in the value of their investment.
• Employees: The merger could lead to changes in the company's organizational structure and operations.
• Customers: The merger could result in an expanded product offering and improved customer service.
• Suppliers: The merger could lead to changes in the company's supply chain.
• Creditors: The merger could affect the company's creditworthiness.

Next Steps

• The company will proceed with the planned merger with Quanterix Corporation, subject to the satisfaction of closing conditions.
• The company will continue to operate its business as a wholly-owned subsidiary of Quanterix following the completion of the merger.

Key Dates

Keywords

corporate governance, executive compensation, directors, executive officers, financial reporting, Akoya Biosciences, Form 10-K, Amendment No. 1